Skip to content
2000
Volume 20, Issue 12
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

One of the major challenges currently facing cancer therapy is the development of drug resistance either intrinsically or as a result of treatment. Treatment evasion is mediated by an intricate web of signalling cascades and adaptations caused by selective therapeutic pressure, leading to metastatic spread and patient death. Hence, discovering and designing novel therapeutic compounds and regimens based on specific alterations in the cancer microenvironment and capable of overcoming resistance to traditional therapies is necessary to improve cancer survival outcomes. These new therapeutic modalities should exhibit improved solubility, penetration capacity and bioavailability in the tumor microenvironment as well as enhanced target specificity compared to old generation compounds. The success of this endeavour will contribute to the advent of precision medicine leading to personalized therapeutic approaches for patients.

Loading

Article metrics loading...

/content/journals/cdm/10.2174/138920022012200102095006
2019-10-01
2025-06-12
Loading full text...

Full text loading...

/content/journals/cdm/10.2174/138920022012200102095006
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test